Transferrin receptor binding proteins for treating brain tumors
AssigneeJanssen Biotech, Inc.
InventorsWan Cheung CHEUNG, Suzanne EDAVETTAL, James PATTERSON, Matthew BUSCHMAN, Justin SCHEER, Fern SHA, Isha TANEJA
Life of this patent
Estimating the term…
Abstract
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a third antigen-binding region capable of binding specifically to transferrin receptor (TfR).
Claims23
A multispecific antibody or antigen binding fragment thereof comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a third antigen-binding region capable of binding specifically to transferrin receptor (TfR), wherein:
- (1) the first antigen-binding region comprises:
- a first heavy chain variable region (VH1) comprising a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 5, 6 and 7, respectively;
- and a first light chain variable region (VL1) comprising a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 8, 9 and 10, respectively;
- (2) the second antigen-binding region comprises:
- second heavy chain variable region (VH2) comprising a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 13, 14 and 15, respectively;
- and a second light chain variable region (VL2) comprising a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 16, 17 and 18, respectively;
- and
- (3) the third antigen-binding region comprises a first single chain variable fragment (scFv1) having:
- a third heavy chain variable region (VH3) comprising a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, and a third light chain variable region (VL3) comprising a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have any of the amino acid sequences of Table 2.
The multispecific antibody or antigen binding fragment thereof of claim 2, wherein:
- (1) the VH1 an amino acid sequence identical to the VH of the HC sequence identified as SEQ ID NO:
- 1;
- and the VL1 comprises an amino acid sequence identical to the VL of the LC sequence identified as SEQ ID NO:
- 2;
- (2) the VH2 an amino acid sequence identical to the VH of the HC sequence identified as SEQ ID NO:
- 11;
- and the VL2 comprises an amino acid sequence identical to the VL of the LC sequence identified as SEQ ID NO:
- 12;
- and
- (3) the VH3 and the VL3 comprise amino acid sequences are identical to the respective VH and VL of a scFv identified as:
- (i) SEQ ID NO:
- 19;
- (ii) SEQ ID NO:
- 26;
- (iii) SEQ ID NO:
- 33;
- (iv) SEQ ID NO:
- 40;
- (v) SEQ ID NO:
- 47;
- (vi) SEQ ID NO:
- 54;
- (vii) SEQ ID NO:
- 59;
- (viii) SEQ ID NO:
- 66;
- (ix) SEQ ID NO:
- 72;
- (x) SEQ ID NO:
- 79;
- (xi) SEQ ID NO:
- 82;
- (xii) SEQ ID NO:
- 85;
- (xiii) SEQ ID NO:
- 87;
- (xiv) SEQ ID NO:
- 94;
- (xv) SEQ ID NO:
- 101;
- (xvi) SEQ ID NO:
- 104;
- (xvii) SEQ ID NO:
- 111;
- (xviii) SEQ ID NO:
- 118;
- (xix) SEQ ID NO:
- 125;
- (xx) SEQ ID NO:
- 132;
- (xxi) SEQ ID NO:
- 138;
- (xxii) SEQ ID NO:
- 144;
- (xxiii) SEQ ID NO:
- 150;
- (xxiv) SEQ ID NO:
- 155;
- (xxv) SEQ ID NO:
- 158;
- (xxvi) SEQ ID NO:
- 164;
- (xxvii) SEQ ID NO:
- 169;
- (xxviii) SEQ ID NO:
- 175;
- (xxix) SEQ ID NO:
- 183;
- (xxx) SEQ ID NO:
- 188;
- (xxxi) SEQ ID NO:
- 193;
- (xxxii) SEQ ID NO:
- 198;
- or
- (xxxiii) SEQ ID NO:
- 204.
(canceled)
(canceled)
-32.
Dependencies are inferred from the claim text.